BIOMERICA SIGNS EXCLUSIVE COMMERCIAL AGREEMENT WITH MAXHEALTH IN CHINA，YAFO CAPITAL ACTED AS THE EXCLUSIVE FINANCIAL ADVISOR ON THIS TRANSACTION

MaxHealth to distribute Biomerica’s colorectal screening test to help identify the early warning signs of colorectal cancer.

June 05, 2019 08:19 ET | Source: Biomerica, Inc.

IRVINE, Calif., June 05, 2019 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) announced it has signed an exclusive sales and distribution agreement with MaxHealth for the sale of its EZ Detect product in China. The agreement requires MaxHealth to meet annual minimum purchase requirements, which in aggregate, equal $17 million. As previously announced, the CFDA has already cleared Biomerica’s EZ Detect™ colorectal screening test for distribution in China.

Biomerica’s EZ Detect colorectal screening test is the simplest at home test to detect fecal occult (hidden) blood, an early warning sign of colorectal cancer. The test does not require handling of stool or dietary restrictions.

“Colorectal cancer is a leading cause of cancer death worldwide, and early detection is the key to saving lives in affected patients,” said Zack Irani, CEO of Biomerica. “Many patients don’t utilize colorectal cancer screening tests due to the requirement of handling stool. EZ Detect was preferred 9:1 by patients versus other tests, in a study at the Johns Hopkins University, since it does not require any handling of the stool. Further, in counties like China with socialized medicine, EZ Detect is the least expensive way to screen populations since there is no mailing of samples and no laboratory processing.”

About Biomerica (NASDAQ: BMRA)

Biomerica, Inc. (www.biomerica.com) is a global biomedical company that develops, manufactures and markets advanced diagnostic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for the early detection of medical conditions and diseases. Biomerica primarily focuses on products for Gastrointestinal Disease, Diabetes and esoteric testing.

About Maxhealth Medical Group Co.,Ltd

Maxhealth Medical Group (www.maxhealthpharm.com) is established in 2009 in Wuxi, Jiangsu Province. Maxhealth is the leading platform with commercialization of innovative medical technology (License-In + CSO). Maxhealth was listed NEEQ in 2016. Maxhealth’s core business-products are in the fields of digestion, neurology, neurology rehabilitation and female health.

About Yafo Capital

Shanghai Yafo Capital (www.yafocapital.com), as a boutique fund management and investment banking firm, specializes in cross-border private equity and M&A transactions. Headquartered in Shanghai, with offices in the US, Israel, Japan, and UK, Yafo Life Science is the healthcare arm under Yafo Capital, with a focus on global pharmaceutical and medical device companies that have a ‘China Angle’. Yafo Life Science is dedicated to bridge the global medical technologies and China market and capital.

美国Biomerica与江苏美安医药签署商业合作协议，雅法资本担任独家财务顾问

2019年6月5日，美国医药上市公司Biomerica, Inc. (股票代码BMRA，以下简称“Biomerica”)宣布与 MaxHealth（江苏美安医药，以下简称“美安医药”）签订中国独家销售其EZ Detect™产品的许可协议（以下简称“协议”）。 雅法资本担任本次交易独家财务顾问。

根据协议，美安医药需达到累计总额为1700万美元的最低采购量，及支付100万美元的预付款。EZ Detect™已获得中国食品药品监督管理总局的销售许可。粪便潜血为结直肠癌的早期症状，Biomerica的EZ Detect™直肠筛查测试是最简便的家用检测粪便潜血的方式。

Biomerica的CEO Zack Irani表示，“结直肠癌是全世界发病率和死亡率的最高癌症之一，对其早期的检测和发现是拯救患者生命的关键。因为粪便检查取样的麻烦，很多患者不重视结直肠癌的检测。约翰·霍普金斯大学的一项研究表明，90% 的患者倾向于选择EZ Detect。同时，作为一种不需要邮寄也不需要实验室处理的便隐血检测产品，EZ Detec是最实惠和方便的检测方法”。

关于Biomerica (股票代码: BMRA)
 

Biomerica, Inc.（www.biomerica.com）是一家全球生物医药公司，专注于开发、制造和销售疾病检测的先进诊断产品。公司目前有五十多种已上市产品，涵盖过敏，溃疡，癌症，不孕和糖尿病等领域。公司在消化领域的在研产品更是覆盖了肠易激综合症，消化不良，溃疡性结肠炎，克罗恩病和胃食管反流病等领域。

关于江苏美安医药（股票代码NEEQ:836163）
 

江苏美安医药（www.maxhealthpharm.com）2009年成立于无锡市，是中国领先的创新医药产品商业化平台（License-in+CSO）。美安医药与全球500强医药企业在中国市场进行市场准入和学术营销合作，通过自有GSP平台，承担医药企业在中国的独家经销商或进口商。此外，美安医药还对海外医疗创新企业进行投资及合资，并通过代理分销、技术转让、合作研发、生产、销售等方式帮助创新技术在中国商业化。

关于雅法资本
 

上海雅法资本(www.yafocapital.com) 作为新型投资和金融服务机构，致力于海外高科技项目的投资、融资和海外并购，总部位于上海，在美国、以色列、日本、及英国均设有分支机构。雅法全球医疗（Yafo Life Science）是雅法资本旗下的医疗大健康部门，专注于帮助具有“中国角度”的海外医药、医疗器械企业在中国的融资、授权和战略合作；为中国医疗企业提供海外市场研究服务，寻找海外投资、并购标的，及药品和器械的商业合作。雅法全球医疗致力于成为全球医疗技术对接中国市场与资本的桥梁。目前覆盖以色列、美国、瑞士、日本等八个医疗创新能力最强的国家。